期刊
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
卷 37, 期 1, 页码 487-501出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2021.2020773
关键词
Bilirubin; hyperbilirubinaemia; jaundice; antioxidant
Bilirubin is the final product of haem catabolism, and disruptions in its metabolic pathways can lead to increased plasma concentration, which may cause brain damage. However, bilirubin also has antioxidant and anti-inflammatory properties, making it a potential treatment for various diseases. This review discusses pharmaceutical strategies to reduce plasma bilirubin concentration and the therapeutic effects of bilirubin in different disorders.
Bilirubin (BR) is the final product of haem catabolism. Disruptions along BR metabolic/transport pathways resulting from inherited disorders can increase plasma BR concentration (hyperbilirubinaemia). Unconjugated hyperbilirubinemia may induce BR accumulation in brain, potentially causing irreversible neurological damage, a condition known as BR encephalopathy or kernicterus, to which newborns are especially vulnerable. Numerous pharmaceutical strategies, mostly based on hemoperfusion, have been proposed over the last decades to identify new valid, low-risk alternatives for BR removal from plasma. On the other hand, accumulating evidence indicates that BR produces health benefits due to its potent antioxidant, anti-inflammatory and immunomodulatory action with a significant potential for the treatment of a multitude of diseases. The present manuscript reviews both such aspects of BR pharmacology, gathering literature data on applied pharmaceutical strategies adopted to: (i) reduce the plasma BR concentration for preventing neurotoxicity; (ii) produce a therapeutic effect based on BR efficacy in the treatment of many disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据